CO

Cencora IncNYSE COR Stock Report

Last reporting period 30 Jun, 2024

Updated 05 Nov, 2024

Last price

Market cap $B

46.818

Mega

Exchange

XNYS - New York Stock Exchange, Inc

COR Stock Analysis

CO

Avoid

Based on Eyestock quantitative analysis, COR`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

51/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-82.7 %

Greatly overvalued

Market cap $B

46.818

Dividend yield

1.07 %

Shares outstanding

199.45 B

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. The company is headquartered in Conshohocken, Pennsylvania and currently employs 42,000 full-time employees. The firm is focused on improving the lives of people and animals around the world. The company is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. The firm operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

View Section: Eyestock Rating